# A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

> **NCT05048797** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 454 (actual)

## Conditions studied

- Locally Advanced or Metastatic Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Trastuzumab Deruxtecan
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Pembrolizumab
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT05048797
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-28
- **Primary completion:** 2026-04-30
- **Final completion:** 2027-07-30
- **Target enrollment:** 454 (ACTUAL)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05048797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05048797, "A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05048797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*